Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer
T-DM1 therapy in HER2-positive metastatic breast cancer leads to significant spleen enlargement and systemic biochemical changes. Future studies should focus on elucidating the long-term implications of these findings and optimizing monitoring strategies for spleen-related complications.
Authors
- Arif Akyıldız (ORCID: https://orcid.org/0000-0002-4452-2076)
- Sercan Aksoy (ORCID: https://orcid.org/0000-0003-4984-1049)
- Rashad İsmayılov (ORCID: https://orcid.org/0000-0002-7093-2722)
- Najmaddin Abdurrahimli (ORCID: https://orcid.org/0000-0002-5694-5527)
- Murat Tuncel (ORCID: https://orcid.org/0000-0003-2352-3587)
- Deniz Can Güven (ORCID: https://orcid.org/0000-0002-6924-9467)
- Mehmet Ruhi Onur (ORCID: https://orcid.org/0000-0003-1732-7862)
- Aylin Ormancı
Institutions
- Hacettepe University (TR)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1093/jjco/hyae141
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28